These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 31933293

  • 1. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis].
    Oreja-Guevara C, García-Merino JA, Saiz A, Rodríguez-Antigüedad A, Álvarez-Cermeño JC, Estrada-Pérez V, Izquierdo G, Fernández O.
    Rev Neurol; 2019 Dec 17; 69(s02):1-9. PubMed ID: 31933293
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ, CLARITY Study Group.
    Mult Scler; 2011 May 17; 17(5):578-93. PubMed ID: 21228029
    [Abstract] [Full Text] [Related]

  • 3. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E.
    Mult Scler Relat Disord; 2019 Apr 17; 29():157-167. PubMed ID: 30885374
    [Abstract] [Full Text] [Related]

  • 4. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
    Meuth SG, Bayas A, Kallmann B, Kleinschnitz C, Linker R, Rieckmann P, Mäurer M.
    Expert Opin Pharmacother; 2020 Nov 17; 21(16):1965-1969. PubMed ID: 32658554
    [Abstract] [Full Text] [Related]

  • 5. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 6. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis.
    Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A.
    Mult Scler Relat Disord; 2020 Nov 25; 46():102572. PubMed ID: 33296971
    [Abstract] [Full Text] [Related]

  • 7. Cladribine Tablets: A Review in Relapsing MS.
    Deeks ED.
    CNS Drugs; 2018 Aug 25; 32(8):785-796. PubMed ID: 30105527
    [Abstract] [Full Text] [Related]

  • 8. Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study.
    Sorensen PS, Pontieri L, Joensen H, Heick A, Rasmussen PV, Schäfer J, Ratzer R, Pihl CE, Sellebjerg F, Magyari M.
    Mult Scler Relat Disord; 2023 Feb 25; 70():104491. PubMed ID: 36623393
    [Abstract] [Full Text] [Related]

  • 9. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
    [Abstract] [Full Text] [Related]

  • 10. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
    Stępień A, Pogoda-Wesołowska A, Tokarz-Kupczyk E, Słowik A, Puz P, Adamczyk-Sowa M, Kurkowska-Jastrzębska I, Kułakowska A, Chorąży M, Piasecka-Stryczyńska K, Jamróz-Wiśniewska A, Bartosik-Psujek H, Rejdak K.
    Neurol Neurochir Pol; 2023 Feb 04; 57(4):371-378. PubMed ID: 37490356
    [Abstract] [Full Text] [Related]

  • 11. Medicinal Chemistry of Multiple Sclerosis: Focus on Cladribine.
    Biernacki T, Sandi D, Bencsik K, Vécsei L.
    Mini Rev Med Chem; 2020 Feb 04; 20(4):269-285. PubMed ID: 31644403
    [Abstract] [Full Text] [Related]

  • 12. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B.
    Mult Scler Relat Disord; 2022 Jan 04; 57():103385. PubMed ID: 35158476
    [Abstract] [Full Text] [Related]

  • 13. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety.
    Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S.
    Drug Saf; 2020 Jul 04; 43(7):635-643. PubMed ID: 32447743
    [Abstract] [Full Text] [Related]

  • 14. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L, Pfeuffer S, Huntemann N, Schmidt M, Su C, Skuljec J, Aslan D, Hackert J, Kleinschnitz K, Hagenacker T, Pawlitzki M, Ruck T, Kleinschnitz C, Meuth SG, Pul R.
    Mult Scler Relat Disord; 2022 Aug 04; 64():103931. PubMed ID: 35690010
    [Abstract] [Full Text] [Related]

  • 15. Development of oral cladribine for the treatment of multiple sclerosis.
    Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC.
    J Neurol; 2010 Feb 04; 257(2):163-70. PubMed ID: 19921304
    [Abstract] [Full Text] [Related]

  • 16. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G, Cook S, Giovannoni G, Rieckmann P, Sørensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F.
    Mult Scler Relat Disord; 2019 Apr 04; 29():168-174. PubMed ID: 30885375
    [Abstract] [Full Text] [Related]

  • 17. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H, Kaczyński Ł, Górecka M, Rolka M, Wójcik R, Zięba P, Kaczor M.
    Mult Scler Relat Disord; 2021 Apr 04; 49():102769. PubMed ID: 33516133
    [Abstract] [Full Text] [Related]

  • 18. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.
    J Neurol; 2013 Apr 04; 260(4):1136-46. PubMed ID: 23263473
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
    Giovannoni G, Soelberg Sorensen P, Cook S, Rammohan K, Rieckmann P, Comi G, Dangond F, Adeniji AK, Vermersch P.
    Mult Scler; 2018 Oct 04; 24(12):1594-1604. PubMed ID: 28870107
    [Abstract] [Full Text] [Related]

  • 20. Safety and effectiveness of cladribine tablets for multiple sclerosis: Results from a single-center real-world cohort.
    Aerts S, Khan H, Severijns D, Popescu V, Peeters LM, Van Wijmeersch B.
    Mult Scler Relat Disord; 2023 Jul 04; 75():104735. PubMed ID: 37192586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.